Aastrom is acquiring global commercial rights to three marketed autologous cell therapy products. [...] Revenues of those three products were $44 million in 2013. Aastrom will also acquire global manufacturing and production centers located in the United States and Denmark.
Here's a quote from Aastrom's president/CEO: The acquisition of Sanofi's CTRM business is a transformative transaction that positions Aastrom as a fully-integrated global regenerative medicine company." -- Nick Colangelo
ASTM closed last Thursday (02014.04.17; market was closed on Friday) at $3.52. Today (02014.04.21) ASTM opened at $4.00 and spiked to $4.79. Right now (30 minutes into trading) ASTM is at $4.50, up ~28%.
No comments:
Post a Comment